Newsroom

⁹⁹ᵐTc-Maraciclatide Demonstrates Potential to Differentiate Inflammation from Fibrosis in Interstitial Lung Disease

Phase 2 ^99mTc-maraciclatide data presented at SNMMI 2026 Annual Meeting show distinct αvβ3 integrin uptake in patients with ILD

Serac Healthcare Limited has presented Phase 2 data showing that SPECT-CT imaging with ^99mTc-maraciclatide has the potential to identify and differentiate active inflammation from fibrosis in patients with interstitial lung disease (ILD). The findings were presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Los Angeles, USA, taking place from 30 May to 2 June and have been highlighted in an SNMMI press release: “New SPECT Imaging Approach Distinguishes Inflammation from Fibrosis to Optimize Treatment for Lung Disease.”

 First US Presentation of DETECT Data Demonstrates Semi-Quantitative Assessment of Endometriosis Lesions Using ⁹⁹ᵐTc-Maraciclatide

Poster presented at SNMMI 2026 shows standardised uptake metrics align with lesion type and expected levels of angiogenesis, including for superficial peritoneal disease.

Serac Healthcare Limited announces the presentation of a poster at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting reporting semi-quantitative imaging data from the DETECT Phase 2 study of ^99mTc-maraciclatide in endometriosis.

⁹⁹ᵐTc-maraciclatide Abstracts To be Presented at SNMMI 2026

Serac Healthcare Limited announces that two abstracts on ^99mTc-maraciclatide will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting taking place from 30 May to 2 June in Los Angeles, USA.

Endometriosis Imaging Study Published in The Lancet Obstetrics, Gynaecology & Women’s Health Highlights ⁹⁹ᵐTc-maraciclatide as a Promising Diagnostic and Monitoring Tool

Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, ^99mTc-maraciclatide, and the Nuffield Department of Women’s & Reproductive Health at the University of Oxford announce the journal publication of Phase 2 data from the “Detecting Endometriosis expressed inTegrins using teChneTium-99m” (DETECT) imaging study. The paper, published open access online in The Lancet Obstetrics, Gynaecology & Women’s Health, highlights that ^99mTc-maraciclatide has potential as...

Endometriosis Imaging with ⁹⁹ᵐTc-maraciclatide Presented at European Endometriosis Congress 2026

Serac Healthcare Limited announces that two oral presentations on the “Detecting Endometriosis expressed inTegrins using teChneTium-99m” imaging (DETECT) study, have been presented at the 8^th European Endometriosis Congress which took place from 23^rd to 25^th April in Bologna, Italy.

DETECT Abstracts Selected for Oral Presentation at European Endometriosis Congress 2026

Serac Healthcare Limited announces that two abstracts on the “Detecting Endometriosis expressed inTegrins using teChneTium-99m” imaging (DETECT) study, have been selected for oral presentation in the “Best Submitted Abstracts” sessions at the 8^th European Endometriosis Congress taking place from 23^rd to 25^th April in Bologna, Italy.

⁹⁹ᵐTc-maraciclatide Granted FDA Fast Track Designation for the Visualization of Inflammation in Interstitial Lung Disease 

Serac Healthcare Limited announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation to ^99mTc-maraciclatide as a diagnostic SPECT-CT agent for the “visualization of inflammation in the lungs of patients with known and suspected interstitial lung disease (ILD).”

Publication of Clinical Results: ⁹⁹ᵐTc-maraciclatide Demonstrates Excellent Potential as a Whole-Body Imaging Method for Rheumatoid Arthritis

Serac Healthcare announces that the findings from a Phase II study evaluating a novel molecular imaging agent, ^99mTc-maraciclatide, as an imaging marker for rheumatoid arthritis (RA) have been published online in Academic Radiology.

Chapter on 99mTc-maraciclatide Published in the 2025 EANM Technologists’ Guide

Serac Healthcare highlights that a chapter on ^99mTc-maraciclatide as an imaging agent for diagnosing endometriosis was published in the European Association of Nuclear Medicine’s Technologists' Guide 2025, which launched at EANM’s annual congress this week.

Molecular Imaging of Interstitial Lung Disease with Maraciclatide: PREDICT-ILD Data Presented at ERS

Serac Healthcare and the University of Exeter, today announce the first findings from a study evaluating a novel molecular imaging agent, ^99mTc-maraciclatide, as an imaging marker for interstitial lung disease evaluation. The data will be presented at the European Respiratory Society conference taking place from 27 September to 1 October in Amsterdam.

Professor Alan Perkins Awarded MBE for Services to Patient Care and Clinical Science

Serac Life Sciences, the parent company of molecular imaging businesses Serac Healthcare Ltd and Serac Imaging Systems Ltd,  announce that their Scientific Advisor, Professor Alan Perkins, has been awarded a Member of the Order of the British Empire (MBE) in the King’s Birthday Honours in recognition of his outstanding services to patient care and clinical science.

Primary Endpoint Met in the DETECT Endometriosis Imaging Study

Headline Data Presented at the World Congress on Endometriosis

Serac Healthcare Limited and the Nuffield Department of Women’s and Reproductive Health at the University of Oxford announce that the primary endpoint has been met in the “Detecting Endometriosis expressed inTegrins using teChneTium-99m” (DETECT) Phase II imaging study.

Serac Healthcare Announces Successful FDA End of Phase II Meeting for Endometriosis Imaging Agent - Positive Feedback on Phase III Trial Design -  

Serac Healthcare Limited today announced positive feedback from its End of Phase II Meeting with the US Food and Drug Administration (FDA) for the development of ^99mTc-maraciclatide as a diagnostic agent for use with single-photon emission computed tomography (SPECT-CT) for the visualisation and diagnosis of superficial peritoneal endometriosis (SPE) in women aged 16 years of age and older.

DETECT abstract accepted at World Congress on Endometriosis 2025

An abstract on the “Detecting Endometriosis integrins using technetium-99m” (DETECT)  imaging study, has been accepted for oral presentation at the prestigious 16^th World Congress on Endometriosis taking place from 21-24 May in Sydney, Australia.

DETECT Endometriosis Imaging Study Presented at EANM’24

Serac Healthcare Limited announces that its clinical partner, the Nuffield Department of Women’s and Reproductive Health at the University of Oxford, gave a presentation on the “Detecting Endometriosis expressed integrins using technetium-99m” (DETECT) imaging study at the European Association of Nuclear Medicine (EANM) annual congress taking place from 19-23 October in Hamburg, Germany

Poster Presented at MICCAI on AI Joint Classification of Images using ⁹⁹ᵐTc-Maraciclatide

A poster was presented today at the annual conference of the Medical Image Computing and Computer Assisted Intervention Society (MICCAI) taking place from 6-10 October in Marrakesh, Morocco. The poster illustrates the latest methodology used in the ongoing research collaboration with King’s College London to develop AI tools to help clinicians read and interpret scans using ^99mTc-maraciclatide.

EANM DETECT Abstract Published and Presentation Details

An abstract on preliminary data from the DETECT “Detecting Endometriosis expressed integrins using technetium-99m” imaging study, has been published ahead of the upcoming congress of the European Association of Nuclear Medicine (EANM).

Phase II PREDICT-ILD Imaging Study Commences in Interstitial Lung Disease

Serac Healthcare Limited and the University of Exeter today announce that the first patient has been scanned with a novel molecular SPECT imaging agent ^99mTc-maraciclatide in a Phase II study titled ‘PRospective Evaluation of Interstitial Lung Disease progression with quantitative CT (PREDICT-ILD)’.

Paper Accepted at MICCAI on AI Joint Classification of Images using ⁹⁹ᵐTc-Maraciclatide

A paper has been accepted for presentation at the annual conference of the Medical Image Computing and Computer Assisted Intervention Society (MICCAI) taking place from 6-10 October in Marrakesh, Morocco.

Abstract Selected as Top Rated Oral Presentation at EANM on DETECT Study Evaluating ⁹⁹ᵐTc-Maraciclatide as a New Imaging Marker for Endometriosis

An abstract on preliminary data from the DETECT “Detecting Endometriosis expressed integrins using technetium-99m” imaging study, has been selected as a Top Rated Oral Presentation at the annual congress of the European Association of Nuclear Medicine (EANM) taking place from 18-23 October 2024 in Hamburg, Germany.

Expanded Access to Medicine Policy

Adopted by the Company on 09 July 2024

Serac Healthcare is dedicated to developing maraciclatide as a new molecular imaging agent that will have a positive impact on patient health, and to serving patients, patient families and patient communities through education, empathy, and awareness.

⁹⁹ᵐTc-Maraciclatide Granted FDA Fast Track Designation for the Diagnosis of Superficial Peritoneal Endometriosis

London, UK, 2 July 2024. Serac Healthcare Limited, a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation to ^99mTc-maraciclatide as a diagnostic SPECT-CT agent for the visualisation and diagnosis of superficial peritoneal endometriosis in women of 16 years and older.

Continuing Positive Results for Imaging of Endometriosis with ⁹⁹ᵐTc-Maraciclatide

London, UK, 7 June 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, and the Nuffield Department of Women’s and Reproductive Health at the University of Oxford announce that further
data has been presented from the “Detecting Endometriosis expressed integrins using technetium99m” (DETECT) imaging study, indicating that 99mTc-maraciclatide is capable of imaging superficial peritoneal endometriosis, the earliest stage of the disease. The data is being presented in a poster today by Dr Tatjana Gibbons, an investigator on the study from the University of Oxford, at the 7th European Endometriosis Congress taking place from 6-8 June 2024 in Bucharest, Romania.

Imaging with ⁹⁹ᵐTc-Maraciclatide Correlates with Identification of Early-Stage Endometriosis by Laparoscopic Surgery

London, UK, 15 March 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, and the Nuffield Department of Women’s and Reproductive Health at the University of Oxford announce that preliminary data has been presented from the “Detecting Endometriosis expressed integrins using technetium-99m” (DETECT) imaging study, indicating that ⁹⁹ᵐTc-maraciclatide is capable of imaging superficial peritoneal endometriosis, the earliest stage of the disease. The data was presented today by Dr Tatjana Gibbons, an investigator on the study from the University of Oxford, in an oral presentation at the Society for Reproductive Investigation (SRI) annual meeting taking place from 12-16 March 2024 in Vancouver, Canada.

⁹⁹ᵐTc-Maraciclatide Phase I Data Published in Nuclear Medicine Communications

London, UK, 14 March 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, ⁹⁹ᵐTc-maraciclatide, announces the publication of Phase I data demonstrating the safety, biodistribution and radiation dosimetry of ⁹⁹ᵐTc-maraciclatide in the April 2024 edition of Nuclear Medicine Communications.

Preliminary Data to be Presented Evaluating ⁹⁹ᵐTc-Maraciclatide as a New Imaging Marker for Endometriosis

London, UK, 19th January 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announces that an abstract on the preliminary data from the first cohort of patients in the “Detecting Endometriosis expressed integrins using technetium-99m” imaging (DETECT) study, has been accepted for oral presentation at the Society for Reproductive Investigation (SRI) annual meeting taking place from 12-16 March 2024 in Vancouver, Canada.

Development of a Deep Learning Approach for Analysing Scans of Rheumatoid Arthritis Patients using ⁹⁹ᵐTc-Maraciclatide Presented at the IEEE Nuclear Science Symposium and Medical Imaging Conference 2023

London, UK, 8 November 2023, Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing innovative molecular imaging technologies, announces that a poster is being presented at the Institute of Electrical and Electronics Engineers Nuclear Science Symposium and Medical Imaging Conference 2023 taking place from 4 to 11 November in Vancouver, Canada.

The Development of a Deep Learning Model to Classify Inflammation from ⁹⁹ᵐTc-Maraciclatide Scans Presented at the BNMS Autumn Meeting 2023

London, UK, 31 October 2023, Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing innovative molecular imaging technologies, announces that a poster titled “Automatic Classification of Inflamed Joint Regions in Rheumatoid Arthritis using Deep Networks with ⁹⁹ᵐTc-Maraciclatide Imaging” is being presented at the British Nuclear Medicine Society meeting taking place on 31 October in London.

AI methods for Automated Identification of Regions of Inflammation from ⁹⁹ᵐTc-Maraciclatide Imaging Presented at the World Molecular Imaging Congress 2023

London, UK, 9 September 2023, Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing innovative molecular imaging technologies, announces that a poster titled “Automatic segmentation of regions of inflammation using deep neural networks for ⁹⁹ᵐTc-Maraciclatide gamma camera imaging of rheumatoid arthritis” is being presented at the World Molecular Imaging Society meeting taking place from 5-9 September in Prague, Czech Republic.

Generative Modelling Methods for ⁹⁹ᵐTc-Maraciclatide Presented at the Institute of Electrical and Electronics Engineers (IEEE) Medical Imaging Conference 2022

London, UK, 10 Nov 2022, Serac Healthcare Limited (“Serac Healthcare” or “the Company”), the clinical radiopharmaceutical company developing innovative molecular imaging technologies, announces that an abstract titled ‘Single-Shot Generative Modelling for ⁹⁹ᵐTc-Maraciclatide Imaging’ is being presented today at the IEEE Medical Imaging Conference taking place 5-12 November in Milan, Italy.

Serac Healthcare Partners with University of Oxford to Evaluate the Potential of ⁹⁹ᵐTc-Maraciclatide to Diagnose Endometriosis Non-Invasively

Serac Healthcare Ltd is working with the University of Oxford to investigate whether an experimental image marker (⁹⁹ᵐTc-maraciclatide) that binds to areas of inflammation can be used to visualise endometriosis using a 20-minute scan.

James McCutcheon FCCA, Appointed Chief Financial Officer

Please join us in welcoming James to the Serac Healthcare team. James is an experienced commercial and finance director with over 30 years’ experience in the pharmaceutical and medical device sectors, having held senior finance positions in both large multinationals, as well as smaller fast growing SMEs.

Julie Davis, Appointed Head of Quality Management

Please join us in welcoming Julie to the Serac Life Sciences team as Head of Quality Management. Julie’s career has been spent in life science and radiopharmaceutical drug discovery, most recently consulting with biotech start-ups including leading the development and implementation of operational processes and quality systems.

Jon Barnett PhD, Appointed Head of CMC and Supply Chain

We are pleased to announce that Jon has joined Serac Healthcare Limited as Head of CMC and Supply Chain. With over 20 years’ experience on radiopharmaceutical and biopharmaceutical product development and commercial supply, Jon has extensive experience of leading global functional and cross-functional project / operational teams to deliver new products and life cycle improvements.

Abstract for Presentation at the European League Against Rheumatism (EULAR) Congress 2020

Results from a Phase II study evaluating the potential of 99mTc-maraciclatide to image synovial inflammation at the whole-body level will be presented at the European League Against Rheumatism (“EULAR”) Congress 2020. The oral presentation is titled, “IMAGING NEOANGIOGENESIS IN RHEUMATOID ARTHRITIS (INIRA): WHOLE-BODY SYNOVIAL UPTAKE OF A 99MTC-LABELLED RGD PEPTIDE IS HIGHLY CORRELATED WITH POWER DOPPLER ULTRASOUND” and will be delivered by Dr Laura Attipoe, Guy’s and St Thomas’ NHS Foundation Trust, London, UK.
Citation: Ann Rheum Dis, volume 79, supplement 1, year 2020, page 110
Session: Diagnostics and imaging procedures (Oral Presentations)

Druin Burch FRCP, Appointed Chief Scientific Officer (CSO)

Serac Life Sciences continues to strengthen its management team with the appointment of Dr Druin Burch as Chief Scientific Officer (CSO). Druin is a Consultant Physician at the Oxford University Hospitals NHS Trust, and has three decades experience as a clinician, scientist and writer in the field of developing and testing medical technology.

Abstract for Presentation at the American Congress of Rheumatology (ACR) Congress 2019

Results from an interim analysis of the first 25 patients enrolled in a study evaluating the potential of 99mTc-maraciclatide to image synovial inflammation at the whole-body level will be presented at the American College of Rheumatology (ACR) Congress. The poster is titled, “IMAGING NEOANGIOGENESIS IN RHEUMATOID ARTHRITIS (INIRA): WHOLE-BODY SYNOVIAL UPTAKE OF A 99MTC-LABELLED RGD PEPTIDE IS HIGHLY CORRELATED WITH POWER DOPPLER ULTRASOUND” and will be presented by Dr Laura Attipoe, Guy’s and St Thomas’ NHS Foundation Trust, London, UK.
Date: Sunday, November 10, 2019
Session Title: Imaging Of Rheumatic Diseases Poster I
Session Time: 9:00AM-11:00AM

Pat Butler, Joins as Board Observer and Advisor.

Pat, a qualified Chartered Accountant, is a director of Hikma Pharmaceuticals, Chairman of Aldermore Bank and was formerly a Senior Director at McKinsey & Co. He is also a Governor of the British Film Institute and a trustee of the Resolution Foundation.

Serac Healthcare founded to develop a molecular imaging agent to help rheumatologists manage treatment decisions in their patients with rheumatoid arthritis

Serac Life Sciences Limited (SLS) announces the formation of a new company, Serac Healthcare Limited (SHC), which will develop and commercialise a novel molecular imaging agent for the detection of disease activity in rheumatoid arthritis (RA). SHC, a wholly-owned subsidiary of SLS, has acquired the molecular imaging agent maraciclatide from GE Healthcare. The goal of the company is to enable rheumatologists to “see disease activity” in the joints, informing clinicians and helping them deliver personalised care to their patients.